Menu Search
Equities

Carna Biosciences Inc

4572:TYO

Carna Biosciences Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (JPY)310.00
  • Today's Change-1.00 / -0.32%
  • Shares traded106.70k
  • 1 Year change-62.61%
  • Beta1.4965
Data delayed at least 20 minutes, as of Nov 22 2024 06:30 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in JPYIncome statement in JPYView more

Year on year Carna Biosciences Inc grew revenues 17.24% from 1.39bn to 1.63bn while net income improved from a loss of 1.35bn to a smaller loss of 1.15bn.
Gross margin87.53%
Net profit margin-107.80%
Operating margin-106.92%
Return on assets-42.15%
Return on equity-46.71%
Return on investment-45.45%
More ▼

Cash flow in JPYView more

In 2023, cash reserves at Carna Biosciences Inc fell by 489.95m. Cash Flow from Financing totalled 1.18bn or 72.70% of revenues. In addition the company used 1.68bn for operations while cash used for investing totalled 11.38m.
Cash flow per share-84.69
Price/Cash flow per share--
Book value per share147.09
Tangible book value per share147.06
More ▼

Balance sheet in JPYView more

Carna Biosciences Inc appears to have little financial risk as the company holds a substantial amount of cash on its books with little or no debt.
Current ratio11.74
Quick ratio11.11
Total debt/total equity0.022
Total debt/total capital0.0215
More ▼

Growth rates in JPY

Year on year, growth in earnings per share excluding extraordinary items increased 30.76%.
EPS growth(5 years)--
EPS (TTM) vs
TTM 1 year ago		25.06
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.